Novo Nordisk has a price fix solution for uninsured patients with diabetes, but not for HSA holders or people with normal ...

Novo Nordisk’s (NYSE:NVO) top executive faced a U.S. Senate grilling on Tuesday over the high prices of the company’s weight loss drug Wegovy and diabetes treatment Ozempic, as demand for both ...

U.S. Sen. Bernie Sanders said major PBMs have agreed not to limit coverage of Ozempic and Wegovy if Novo lowers its prices.

Novo Nordisk's top executive faced a Senate grilling on Tuesday over the high prices of the company's weight loss drug Wegovy and diabetes treatment Ozempic, as demand for both injections soars in the ...

Novo Nordisk under political pressure over high U.S. drug prices as CEO testifies before Congress. PBMs and limited impact on ...

Inflation across the economy is cooling, but many Americans are grappling with sticker shock over rising egg prices in the US ...

Novo Nordisk is investing $30 billion to expand production, but middlemen are pocketing 74 cents of every dollar it makes in ...

Discover an untold biotech story and find out how Pfizer missed an opportunity in the GLP-1 market because of an exit in the ...

The Vermont independent says he has secured pledges from the major PBMs that they would not limit coverage of Ozempic and Wegovy if the company lowers its list prices — an announcement that CEO Lars ...

Amgen's immunology drug results —The Novo Nordisk Senate hearing —Sanofi's soul-searching Read on to learn more.

Wednesday's edition of Forbes Daily covers Caroline Ellison's prison sentence, SEC under fire, Nvidia approaches $3 trillion, ...

Visa's stock closed more than 5% lower for the day. Senators grilled Novo Nordisk CEO Lars Fruergaard Jørgensen at a hearing on Tuesday over the high prices of the company's blockbuster injections.